Routine antenatal anti-D prophylaxis is recommended as a treatment option for all pregnant women who are RhD negative and who are not known to be 'sensitised'.

When a decision has been made to give routine antenatal anti-D prophylaxis, the treatment with the lowest cost should be used. This should take into account the costs of both obtaining and giving the treatment.

This guidance updates and replaces NICE Technology Appraisal TA 41 (published in May 2002).

  • National Institute for Health and Care Excellence (NICE) accreditation logo